DP-2 Gene SNP Detection for PGD2-Related Hair Growth Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for androgenetic alopecia, such as finasteride and minoxidil, do not fully reverse hair miniaturization, and there is a need to identify subjects responsive to more effective hair growth stimulants, as the role of PGD2 and its receptor DP-2 in hair growth inhibition remains unclear.
Innovation Solution
Administering a DP-2 antagonist, such as AM211, and identifying subjects with specific SNPs in the DP-2 gene, like rs545659, rs634681, and rs7167, to determine responsiveness and stimulate hair growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments like finasteride and minoxidil are used for androgenetic alopecia, then hair growth is stimulated to some extent, but they do not fully reverse hair miniaturization and their effectiveness varies among subjects
Solution Approach 1:
The patent applies parameter changes by identifying specific genetic parameters (SNPs in the DP-2 gene such as rs545659, rs634681, and rs7167) that determine subject responsiveness to PGD2-mediated hair growth inhibition. By analyzing these genetic parameters, the patent enables personalized treatment selection, matching subjects with specific SNP profiles to DP-2 antagonist therapy, thereby improving treatment reliability and adaptability simultaneously
Solution Approach 2:
The patent implements feedback through SNP genotyping analysis that provides information about a subject's likelihood of responding to DP-2 antagonist treatment. This genetic feedback mechanism allows clinicians to predict treatment outcomes before initiating therapy, enabling informed decisions about whether to proceed with DP-2 antagonist treatment or select alternative therapies, thus resolving the contradiction between treatment effectiveness and subject-specific responsiveness
2Reliability
If PGD2 levels are elevated in balding scalp, then hair growth inhibition occurs via DP-2 receptor activation, but the mechanism is not fully understood and treatment options are limited
Solution Approach 1:
The patent applies the extraction principle by isolating and focusing on the specific PGD2-DP-2 signaling pathway as the target for intervention in androgenetic alopecia. By extracting this specific mechanism from the complex web of hair loss pathways, the patent enables targeted therapy using DP-2 antagonists, improving mechanistic understanding while keeping the treatment protocol relatively simple and focused
Solution Approach 2:
The patent uses SNP analysis as an intermediary tool that bridges the gap between understanding the PGD2-DP-2 mechanism and implementing effective treatment. The genetic markers serve as mediators that translate mechanistic knowledge into clinically actionable information, allowing selection of subjects most likely to benefit from DP-2 antagonist therapy without requiring complex diagnostic protocols
Data Source
AI summary
DP-2 antagonists reversed PGD2-mediated human hair growth inhibition in a dose-dependent manner in vitro by reducing PGD2-triggered apoptosis and maintaining proliferation of keratinocytes. Hair follicles from approximately half of the alopecia patients exhibited little susceptibility to PGD2's effect in vitro. SNPs in the human DP-2 gene were identified that are associated with hair growth inhibition by PGD2. These findings underscore the role of DP-2 in regulating hair growth and indicate that DP-2 can be an effective approach in preventing and/or treating androgenetic alopecia in patients sensitive to PGD2. Furthermore, the SNPs identified here can be used to identify patients who will benefit from treatment.